MultiCell Technologies, Inc. (MCET) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MultiCell Technologies, Inc. (MCET) trades at $0.00001 with AI Score 58/100 (Grade B). MultiCell Technologies, Inc. is a biopharmaceutical company focused on developing novel therapeutics and discovery tools for neurological disorders, hepatic disease, cancer, and interventional cardiology. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for MCET: MCET does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MCET against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MCET: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MultiCell Technologies, Inc. (MCET) Healthcare & Pipeline Overview
MultiCell Technologies, Inc. is a biopharmaceutical entity engaged in developing novel therapeutics for neurological disorders, hepatic disease, cancer, and interventional cardiology. The company's pipeline features a Phase II candidate for MS-related fatigue, preclinical cancer therapies, and a bioabsorbable stent, operating with a small team and leveraging strategic licensing agreements.
What Is the Investment Thesis for MCET?
MultiCell Technologies, Inc. presents an investment profile centered on its early-stage biopharmaceutical pipeline and the potential for significant value creation if its therapeutic candidates achieve clinical success. The company's portfolio includes MCT-125, a Phase II candidate for MS-related fatigue, and preclinical/discovery stage assets like MCT-465 and MCT-485 for cancer, alongside the Ideal BioStent for cardiovascular applications. These assets target substantial markets, offering potential for high returns if they advance through rigorous clinical trials and regulatory approvals. However, the company operates with a notable negative profit margin of -770.7% and a market capitalization of $0.00B, reflecting its pre-commercial stage and significant R&D expenditures. The 100.0% gross margin indicates a current focus on intellectual property development rather than product sales. Key value drivers include successful clinical trial outcomes, potential for new licensing agreements, and the ability to secure further funding to support its extensive development efforts. The inherent risks of biotechnology development, including high failure rates and lengthy timelines, are significant considerations.
Based on FMP financials and quantitative analysis
MCET Key Highlights
MultiCell Technologies, Inc. currently holds a market capitalization of $0.00 billion, indicating a very low public valuation.
- The company reported a profit margin of -770.7%, reflecting substantial operating losses typical for a pre-revenue biopharmaceutical firm heavily invested in research and development.
- A gross margin of 100.0% suggests that the company currently incurs no direct cost of goods sold, consistent with its focus on drug discovery and development rather than commercialized product sales.
- The company's Beta is reported as -35.68, an exceptionally unusual figure that may indicate extremely low trading volume, data anomalies, or a highly inverse relationship to market movements, requiring careful interpretation.
- MultiCell Technologies, Inc. operates with a very lean team, employing just two individuals, which highlights its focused R&D model and potentially outsourced operational aspects.
Who Are MCET's Competitors?
MCET is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCET's Key Strengths?
Diverse product pipeline addressing multiple therapeutic areas: neurological disorders, oncology, and cardiovascular applications.
- Existing license agreements with major industry players, Corning Incorporated and Pfizer Inc., validating its technology.
- MCT-125 is in Phase II clinical trials, indicating progress beyond early discovery for a key candidate.
- 100.0% gross margin, reflecting a focus on intellectual property development without significant cost of goods sold.
What Are MCET's Weaknesses?
Significant negative profit margin of -770.7%, indicating substantial ongoing losses and high R&D costs.
- Very small operational team of only two employees, which may limit capacity for extensive development and commercialization efforts.
- Product pipeline is largely in early stages (preclinical and discovery), with high inherent risks of failure.
- Market capitalization of $0.00B suggests an extremely low valuation and potential challenges in attracting significant investment.
What Could Drive MCET Stock Higher?
MCET catalyst: Progression of MCT-125 from Phase II to Phase III clinical trials for the treatment of primary multiple sclerosis-related fatigue, which would signify a major advancement in its lead candidate.
- Successful completion of preclinical studies for MCT-465 and its subsequent entry into human clinical trials for solid tumor cancers, marking a critical step in its oncology pipeline.
- Advancement of the Ideal BioStent through further development stages and potential regulatory milestones for interventional cardiology and peripheral vessel applications.
- Execution of new or expanded licensing agreements with pharmaceutical or medical device partners for any of its pipeline assets, potentially providing non-dilutive funding and validation.
- Public disclosure of clinical data or research findings from its ongoing development programs, particularly for MCT-125, which could influence investor perception and partnership interest.
What Are the Key Risks for MCET?
The company faces significant financial instability, evidenced by a -770.7% profit margin and a $0.00B market cap, indicating substantial losses and a need for continuous capital infusion.
- Its product pipeline is predominantly in early stages (Phase II, preclinical, discovery), carrying inherent high risks of clinical trial failure, regulatory setbacks, and lengthy development timelines.
- MultiCell Technologies operates with only two employees, which may pose operational challenges in managing a diverse pipeline and executing complex clinical development programs effectively.
- The 'OTC Other' listing and 'Unknown' disclosure status severely limit transparency, liquidity, and investor confidence, making it difficult to assess the company's true financial and operational health.
- Intense competition from larger, well-funded biopharmaceutical companies in its target therapeutic areas could hinder market penetration and the ability to secure partnerships or funding.
What Are the Growth Opportunities for MCET?
- **Advancement of MCT-125 for MS-related Fatigue:** The global multiple sclerosis treatment market is substantial, with a significant unmet need for effective treatments for MS-related fatigue, which affects a large percentage of patients and severely impacts quality of life. As MCT-125 is currently in Phase II, successful progression through further clinical trials (Phase III) and eventual regulatory approval could unlock access to a multi-billion dollar market segment. This advancement would represent a critical validation of the company's research and development capabilities, potentially attracting significant partnerships or acquisition interest within a 3-5 year timeline if trials proceed favorably.
- **Development of MCT-465 for Solid Tumor Cancers:** The oncology market, particularly for solid tumors, remains one of the largest and most rapidly expanding therapeutic areas, with annual expenditures in the hundreds of billions globally. MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate, aims to act as a potent immune enhancer. If this candidate successfully transitions from preclinical studies into human clinical trials and demonstrates efficacy, it could tap into a vast market for novel cancer immunotherapies. The timeline for this opportunity is longer, likely 5-10 years to reach commercialization, but the potential market size and demand for innovative cancer treatments are immense.
- **Exploration of MCT-485 with Tumor Cytolytic Properties:** Also targeting various cancers, MCT-485 is a discovery-stage dsRNA therapeutic candidate with unique tumor cytolytic properties. While at an earlier stage than MCT-465, its distinct mechanism of action offers another avenue for addressing oncology needs. The potential for a direct tumor-killing agent, especially one that could be broadly applicable across different cancer types, represents a significant growth opportunity. Success in early discovery and preclinical validation could lead to substantial value creation, with a potential commercialization timeline extending beyond 10 years, but with a market size mirroring the vast oncology landscape.
- **Commercialization of Ideal BioStent for Cardiovascular Applications:** The market for interventional cardiology and peripheral vessel devices, particularly bioabsorbable stents, is a growing segment as these devices offer advantages over permanent metallic stents. Ideal BioStent, being bioabsorbable, aims to restore vessel function after its therapeutic role is complete, potentially reducing long-term complications. Successful clinical development and regulatory approval for this device could position MultiCell Technologies in a competitive medical device market, which is valued in the tens of billions globally. This opportunity could materialize within a 5-7 year timeframe, depending on clinical trial progress and regulatory pathways.
- **Leveraging Strategic Licensing Agreements:** MultiCell Technologies has existing license agreements with major industry players like Corning Incorporated and Pfizer Inc. These partnerships not only provide potential revenue streams but also validate the scientific merit of the company's intellectual property. Future growth can be driven by expanding these existing agreements, securing new licensing deals for its pipeline candidates, or entering into co-development partnerships. Such collaborations can provide crucial non-dilutive funding, access to larger development resources, and broader market reach, accelerating the path to commercialization for its assets and diversifying its revenue potential over a 2-7 year horizon.
What Threats Does MCET Face?
- High failure rates inherent in biopharmaceutical clinical trials, potentially leading to significant financial losses.
- Intense competition from larger, well-funded pharmaceutical and medical device companies.
- Challenges in securing sufficient capital to fund lengthy and expensive research and development programs.
- Regulatory hurdles and lengthy approval processes for both drug candidates and medical devices.
- Limited transparency and liquidity risks associated with its OTC Other market classification and unknown disclosure status.
What Are MCET's Competitive Advantages?
- Proprietary drug candidates and medical device technology, including specific dsRNA therapeutics and the Ideal BioStent.
- Specialized focus on challenging therapeutic areas such as MS-related fatigue, specific cancer types, and bioabsorbable stents.
- Existing license agreements with established industry players like Corning Incorporated and Pfizer Inc., validating its intellectual property.
- Early-stage pipeline development in novel therapeutic modalities, potentially offering first-in-class or best-in-class treatments.
- Accumulated scientific expertise and research data in its niche areas of biopharmaceutical and medical device development.
What Does MCET Do?
MultiCell Technologies, Inc., headquartered in Woonsocket, Rhode Island, is a biopharmaceutical company with a foundational history dating back to its establishment in 1962, originally incorporated as Exten Industries, Inc. The company underwent a significant rebranding in April 2004, adopting its current name to better reflect its evolving focus on cellular and molecular technologies. MultiCell Technologies is dedicated to the discovery and development of novel therapeutics and advanced discovery tools, targeting a diverse range of critical medical conditions including neurological disorders, hepatic disease, various forms of cancer, and applications within interventional cardiology and peripheral vessel treatments. Its product portfolio is characterized by several key candidates at different stages of development. These include MCT-125, a therapeutic candidate currently in Phase II clinical trials, specifically designed to address primary multiple sclerosis-related fatigue. In the oncology space, the company is advancing MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate recognized for its potent immune-enhancing properties, intended for the treatment of solid tumor cancers. Additionally, MCT-485 is a discovery-stage dsRNA therapeutic candidate that exhibits tumor cytolytic properties, being explored for its potential in treating various cancers. Beyond drug development, MultiCell Technologies is also involved in the medical device sector with Ideal BioStent, a bioabsorbable stent designed for use in interventional cardiology and peripheral vessel applications. The company has strategically secured license agreements with prominent industry players, Corning Incorporated and Pfizer Inc., which underscore its collaborative approach to research and development. Operating with a lean structure of two employees, MultiCell Technologies maintains a focused approach on its specialized therapeutic areas.
What Products and Services Does MCET Offer?
- Develops novel therapeutics for neurological disorders, including a Phase II candidate for multiple sclerosis-related fatigue.
- Engages in the discovery and preclinical development of synthetic double-stranded RNA (dsRNA) therapeutics for solid tumor cancers.
- Researches discovery-stage dsRNA therapeutic candidates with tumor cytolytic properties for various cancer treatments.
- Designs and develops bioabsorbable stents for use in interventional cardiology and peripheral vessel applications.
- Holds license agreements with Corning Incorporated and Pfizer Inc., indicating collaborations on its intellectual property.
- Focuses on a pipeline of early-stage biopharmaceutical assets and medical devices.
- Operates as a research and development-centric biopharmaceutical company.
How Does MCET Make Money?
- Primarily focused on research and development (R&D) of novel drug candidates and medical devices.
- Aims to advance its product pipeline through preclinical and clinical trial stages to demonstrate safety and efficacy.
- Seeks to monetize its intellectual property through licensing agreements with larger pharmaceutical or medical device companies.
- Potential future revenue generation from direct sales of approved pharmaceutical products or medical devices.
- Relies on securing funding, potentially through equity financing or partnerships, to support its extensive R&D activities.
What Industry Does MCET Operate In?
MultiCell Technologies, Inc. operates within the highly specialized and capital-intensive biotechnology industry, a sector characterized by long development cycles, significant regulatory hurdles, and high-risk, high-reward potential. The company's focus areas—neurological disorders, oncology, hepatic disease, and interventional cardiology—represent large and growing markets with substantial unmet medical needs. MultiCell Technologies positions itself as an innovator in these fields, developing novel therapeutics and discovery tools. The competitive landscape is intense, featuring both large pharmaceutical companies with extensive resources and numerous smaller biotech firms vying for breakthroughs. MultiCell Technologies, with its early-stage pipeline and limited employee base, faces the challenge of advancing its candidates against established players, relying on the unique potential of its specific drug mechanisms and stent technology to carve out a niche.
Who Are MCET's Key Customers?
- Patients suffering from neurological disorders, particularly multiple sclerosis-related fatigue.
- Patients diagnosed with solid tumor cancers and other forms of cancer.
- Patients requiring interventional cardiology or peripheral vessel procedures who could benefit from bioabsorbable stents.
- Pharmaceutical companies and medical device manufacturers seeking to license or acquire novel therapeutic candidates or technologies.
- Healthcare providers and hospitals that would prescribe or utilize the company's approved products.
How MultiCell Technologies, Inc. Is Valued
Relative to its peer group, MCET's quantitative score of 58/100 is below the peer average of 76/100.
Company Profile
MultiCell Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Woonsocket, US. The company is led by CEO W. Gerald Newmin. MCET has traded publicly since 2000.
Key Financial Metrics
Return on equity for MultiCell Technologies, Inc. stands at 164.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.11 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
MultiCell Technologies, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
MCET Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse product pipeline addressing multiple therapeutic areas: neurological disorders, oncology, and cardiovascular applications.
- Existing license agreements with major industry players, Corning Incorporated and Pfizer Inc., validating its technology.
- MCT-125 is in Phase II clinical trials, indicating progress beyond early discovery for a key candidate.
- 100.0% gross margin, reflecting a focus on intellectual property development without significant cost of goods sold.
Bear Case
- Significant negative profit margin of -770.7%, indicating substantial ongoing losses and high R&D costs.
- Very small operational team of only two employees, which may limit capacity for extensive development and commercialization efforts.
- Product pipeline is largely in early stages (preclinical and discovery), with high inherent risks of failure.
- Market capitalization of $0.00B suggests an extremely low valuation and potential challenges in attracting significant investment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MCET Latest News
No recent news available for MCET.
MCET Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCET.
Price Targets
Wall Street price target analysis for MCET.
MCET MoonshotScore
What does this score mean?
The MoonshotScore rates MCET 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: W. Gerald Newmin
Chief Executive Officer
The specific career history, educational background, and previous roles of W. Gerald Newmin are not detailed in the provided information. He is identified as managing the company's two employees, indicating a direct leadership role in the company's operations and strategic direction.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to W. Gerald Newmin's leadership are not provided in the source data. His role involves managing the company's limited personnel and overseeing its biopharmaceutical development efforts.
MCET OTC Market Information
MultiCell Technologies, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, public float, and corporate governance, OTC Other companies have minimal or no financial reporting requirements. This tier is typically home to penny stocks, distressed companies, or those with limited public information. Investors in this tier face significantly higher risks due to the lack of transparency and regulatory oversight compared to higher OTC tiers (e.g., OTCQX, OTCQB) or national exchanges.
- OTC Tier: OTC Other
- **Limited Transparency:** The 'Unknown' disclosure status means investors have little to no access to current financial statements, operational updates, or other material information, hindering informed decision-making.
- **Low Liquidity and High Volatility:** Trading on the OTC Other tier typically involves very low trading volumes, leading to wide bid-ask spreads and extreme price fluctuations, making it difficult to enter or exit positions.
- **Lack of Regulatory Oversight:** Companies on the OTC Other tier are subject to minimal regulatory scrutiny compared to those on major exchanges, increasing the risk of fraud or misleading information.
- **Difficulty in Valuation:** Without reliable financial data and consistent trading, accurately valuing the company's shares becomes highly speculative and challenging.
- **Potential for Delisting/Dormancy:** Companies in this tier may cease operations or become completely dormant without public notice, leading to a total loss of investment.
- Attempt to locate any available public filings or press releases, however infrequent, to glean operational updates.
- Investigate the background and track record of W. Gerald Newmin and any other key personnel, if information can be found.
- Research the scientific validity and market potential of its pipeline candidates (MCT-125, MCT-465, MCT-485, Ideal BioStent).
- Assess the status and terms of its license agreements with Corning Incorporated and Pfizer Inc., if details are publicly available.
- Evaluate the company's funding status and any indications of recent capital raises or financial distress.
- Consider the regulatory environment for its specific drug and device candidates and potential timelines.
- Understand the historical trading patterns and volume, if any, to gauge liquidity and price stability.
- **Long Operating History:** Founded in 1962, the company has existed for several decades, suggesting a historical operational presence.
- **Specific Product Pipeline:** The company details a specific pipeline of drug candidates (MCT-125, MCT-465, MCT-485) and a medical device (Ideal BioStent) with defined therapeutic targets and development stages.
- **Strategic License Agreements:** The existence of license agreements with established companies like Corning Incorporated and Pfizer Inc. suggests external validation of its intellectual property or technology.
- **Defined Therapeutic Focus:** The company's focus on specific areas like neurological disorders, oncology, and interventional cardiology indicates a clear business objective.
- **Headquarters Location:** Being headquartered in Woonsocket, Rhode Island, provides a physical address, which is a basic signal of an operating entity.
MultiCell Technologies, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for MCET?
MCET holds an AI Score of 58/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. MultiCell Technologies, Inc. is a biopharmaceutical company focused on developing novel therapeutics and discovery tools for neurological disorders, hepatic disease, cancer, and interventional …
What does MultiCell Technologies, Inc. do?
MultiCell Technologies, Inc. is a biopharmaceutical company dedicated to developing novel therapeutics and discovery tools across several critical medical fields. Its primary focus areas include neurological disorders, hepatic disease, various forms of cancer, and interventional cardiology with peripheral vessel applications. The company's portfolio features MCT-125, a Phase II therapeutic candidate targeting multiple sclerosis-related fatigue.
What is MultiCell Technologies, Inc.'s drug pipeline status?
MultiCell Technologies, Inc. maintains a pipeline of therapeutic candidates at various stages of development. Its most advanced candidate is MCT-125, which is currently in Phase II clinical trials for the treatment of primary multiple sclerosis-related fatigue. This represents a significant step beyond initial research.
What are the main risks for MCET?
MultiCell Technologies, Inc. faces several significant risks inherent to its stage of development and market listing. Financially, the company exhibits a substantial negative profit margin of -770.7% and a $0.00B market capitalization, indicating ongoing operational losses and a high dependency on future funding.
What are the key factors to evaluate for MCET?
MultiCell Technologies, Inc. (MCET) holds an AI score of 58/100 (moderate). presents an investment profile centered on its early-stage biopharmaceutical pipeline and the potential for significant value creation if its therapeutic candidates achieve clinical success. Not financial advice.
How frequently does MCET data refresh on this page?
MCET's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MCET's recent stock price performance?
MultiCell Technologies, Inc. (MCET) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product pipeline addressing multiple therapeutic areas: neurological disorders, oncology, and cardiovascular applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MCET overvalued or undervalued right now?
MultiCell Technologies, Inc. (MCET) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MCET before investing?
Before investing in MultiCell Technologies, Inc. (MCET), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly limited to the provided source data. Details on CEO background, specific clinical trial progress, market sizes for individual products, and competitor analysis are not available.
- The extremely unusual Beta value of -35.68 is reported as given, without further interpretation beyond its numerical value, as per content rules against speculation.
- The 'Unknown' disclosure status for OTC analysis is a significant limitation for comprehensive due diligence.